AC Immune (NASDAQ:ACIU) Trading Down 4.4% – Time to Sell?

AC Immune SA (NASDAQ:ACIU)’s share price fell 4.4% during trading on Wednesday . The company traded as low as $2.75 and last traded at $2.80. 71,081 shares traded hands during mid-day trading, a decline of 45% from the average session volume of 128,556 shares. The stock had previously closed at $2.93.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of AC Immune in a research note on Friday, November 15th. StockNews.com cut AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st.

AC Immune Stock Down 2.9 %

The company has a fifty day simple moving average of $3.05 and a 200 day simple moving average of $3.31. The firm has a market capitalization of $269.12 million, a P/E ratio of -5.91 and a beta of 1.29.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Vanguard Capital Wealth Advisors bought a new position in AC Immune in the second quarter valued at about $56,000. China Universal Asset Management Co. Ltd. increased its position in AC Immune by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock worth $72,000 after buying an additional 7,400 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in AC Immune in the second quarter worth about $218,000. Geode Capital Management LLC increased its position in AC Immune by 6.4% in the third quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock worth $220,000 after buying an additional 3,499 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in AC Immune by 26.4% in the second quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock worth $2,602,000 after buying an additional 136,300 shares in the last quarter. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.